HARMONIZE
Sodium Zirconium Cyclosilicate in Hyperkalaemia
Patient / Population Intervention / Exposition Comparaison Critère de jugement
In 258 patients with hyperkalaemia, sodium zirconium cyclosilicate maintained normokalaemia compared with placebo.
N
258
Schéma
Phase 3 RCT with an open-label run-in
Critère
Mean serum potassium during days 8–29
Pertinence
3
RésultatMean serum potassium days 8–29: 4.8/4.5/4.4 mEq/L (5/10/15 g) vs 5.1 with placebo (all p<0.001).
Kosiborod M, et al. JAMA. 2014;312(21):2223-2233. 10.1001/jama.2014.15688
Discussion et critique
Led to approval of sodium zirconium cyclosilicate (Lokelma) for hyperkalaemia.